ANDA 77904, held by Cipla. Pravastatin Sodium.
As of Nov 16, 2026, ANDA 77904 (Pravastatin Sodium), held by Cipla, was first approved by FDA on Mar 22, 2016, with 2 approved supplements and 0 published complete response letters.
| Mar 22, 2016 | Original application | Approved | None posted |
| Oct 23, 2006 | Original application | Approved | None posted |
| Pravastatin Sodium10MG · tablet;oral | Pravastatin Sodium | Rx |
| Pravastatin Sodium20MG · tablet;oral | Pravastatin Sodium | Rx |
| Pravastatin Sodium40MG · tablet;oral | Pravastatin Sodium | Rx |
| Pravastatin Sodium80MG · tablet;oral | Pravastatin Sodium | Rx |
| Jul 2, 2025 | Supplement 7Labeling · Standard review | Approved | None posted |
| Nov 14, 2016 | Supplement 3Labeling · Standard review | Approved | None posted |
| Mar 22, 2016 | Original application | Approved | None posted |
| Oct 23, 2006 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters